Intellia Therapeutics Inc... (NTLA)
| Bid | 12.1 |
| Market Cap | 1.25B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -5.45 |
| PE Ratio (ttm) | -2.25 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 12.3 |
| Volume | 4,180,145 |
| Avg. Volume (20D) | 3,354,733.7 |
| Open | 12.53 |
| Previous Close | 12.28 |
| Day's Range | 12.03 - 12.84 |
| 52-Week Range | 8.96 - 34.87 |
| Beta | undefined |
About NTLA
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline...
Analyst Forecast
According to 17 analyst ratings, the average rating for NTLA stock is "Buy." The 12-month stock price forecast is $54, which is an increase of 341.18% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
19 hours ago · accessnewswire.com
April 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NTLANEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal ...
